{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:33:35Z","timestamp":1794501215636,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We aimed to assess the effect of SGLT2i on arrhythmias by conducting a meta-analysis using data from randomized controlled trials(RCTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardioprotective effects via multiple mechanisms that may also contribute to decrease arrhythmias risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched in databases (PubMed, Embase, Cochrane Library, and clinicaltrials.gov) up to April 2023. RCTs comparing SGLT2i with placebo were included. The effects of SGLT2i on atrial fibrillation(AF), atrial flutter(AFL), composite AF\/AFL, ventricular fibrillation(VF), ventricular tachycardia(VT), ventricular extrasystoles(VES), sudden cardiac death(SCD) and composite VF\/VT\/SCD were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>33 placebo-controlled RCTs were included, comprising 88,098 patients (48,585 in SGLT2i vs. 39,513 in placebo). The mean age was 64.9\u2009\u00b1\u20099.4\u00a0years, 63.0% were male. The mean follow-up was 1.4\u2009\u00b1\u20091.1\u00a0years. The pooled-results showed that SGLT2i was associated with a significantly lower risk of AF [risk ratio(RR): 0.88, 95% confidence interval(CI) 0.78\u20131.00, P\u2009=\u20090.04] and composite AF\/AFL (RR: 0.86, 95%CI 0.77\u20130.96, P\u2009=\u20090.01). This favorable effect appeared to be substantially pronounced in patients with HFrEF, male gender, dapagliflozin, and\u2009&gt;\u20091\u00a0year follow-up. For SCD, only in heart failure patients, SGLT2i were found to be associated with a borderline lower risk of SCD (RR: 0.67, P\u2009=\u20090.05). No significant effects of SGLT2i on other ventricular arrhythmic outcomes were found.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SGLT2i lowers the risks of AF and AF\/AFL, and this favorable effect appeared to be particularly pronounced in patients with HFrEF, male gender, dapagliflozin, and longer follow-up (&gt;\u20091\u00a0year). SGLT2i lowers the risk of SCD only in heart failure patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02137-x","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T11:02:20Z","timestamp":1708772540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of\u2009&gt;\u200980,000 patients (the SGLT2i\u2014Arrhythmias\u00a0and\u00a0Sudden Cardiac Death)"],"prefix":"10.1186","volume":"23","author":[{"given":"Jia","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Martinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Futyma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Di Vece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Schratter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem-Jan","family":"Acou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio G.","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"P\u00fcrerfellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Templin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"issue":"40","key":"2137_CR1","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126.","journal-title":"Eur Heart J"},{"issue":"5","key":"2137_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the european society of cardiology (esc) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"key":"2137_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fphys.2018.00835","volume":"9","author":"Z Xiong","year":"2018","unstructured":"Xiong Z, Liu T, Tse G, Gong M, Gladding PA, Smaill BH, et al. A machine learning aided systematic review and meta-analysis of the relative risk of atrial fibrillation in patients with diabetes mellitus. Front Physiol. 2018;9:835.","journal-title":"Front Physiol"},{"issue":"6","key":"2137_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.numecd.2018.02.011","volume":"28","author":"D Aune","year":"2018","unstructured":"Aune D, Schlesinger S, Norat T, Riboli E. Diabetes mellitus and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28(6):543\u201356.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2137_CR5","doi-asserted-by":"publisher","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","volume":"91","author":"WH Maisel","year":"2003","unstructured":"Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D-8D.","journal-title":"Am J Cardiol"},{"issue":"18","key":"2137_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/eurheartj\/ehz553","volume":"41","author":"M Packer","year":"2020","unstructured":"Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757\u201363.","journal-title":"Eur Heart J"},{"issue":"8","key":"2137_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/01.RES.0000145047.14691.db","volume":"95","author":"GF Tomaselli","year":"2004","unstructured":"Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95(8):754\u201363.","journal-title":"Circ Res"},{"key":"2137_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, ESC Scientific Document Group, et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"5","key":"2137_CR9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190\u20135.","journal-title":"Diabetes"},{"issue":"2","key":"2137_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig. 2014;124(2):499\u2013508.","journal-title":"J Clin Investig"},{"issue":"7","key":"2137_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"H Heerspink","year":"2019","unstructured":"Heerspink H, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154\u201366.","journal-title":"Diabetologia"},{"issue":"4","key":"2137_CR12","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/jcp.26760","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234(4):3231\u20137.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2137_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"HC Lee","year":"2019","unstructured":"Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2137_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36(4):543\u201353.","journal-title":"Can J Cardiol"},{"issue":"15","key":"2137_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the declare-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"1","key":"2137_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","volume":"19","author":"AW Ling","year":"2020","unstructured":"Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2137_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2137_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GH, Feng Q, Fei Y, Tse YK, Wu MZ, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2137_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","volume":"24","author":"D Sfairopoulos","year":"2022","unstructured":"Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022;24(1):20\u201330.","journal-title":"Europace"},{"issue":"7","key":"2137_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098\u2013105.","journal-title":"Heart Rhythm"},{"issue":"2","key":"2137_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip G. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25(2):602\u201310.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2137_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","volume":"19","author":"AW Ling","year":"2020","unstructured":"Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2137_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):165.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2137_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"key":"2137_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117414","volume":"247","author":"D Wei","year":"2020","unstructured":"Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro. Life Sci. 2020;247: 117414.","journal-title":"Life Sci"},{"issue":"3","key":"2137_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/CIRCRESAHA.111.253229","volume":"110","author":"N Li","year":"2012","unstructured":"Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, et al. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ Res. 2012;110(3):465\u201370.","journal-title":"Circ Res"},{"issue":"4","key":"2137_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. Esc Heart Fail. 2018;5(4):642\u20138.","journal-title":"Esc Heart Fail"},{"issue":"1","key":"2137_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2137_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"E Bertero","year":"2018","unstructured":"Bertero E, Prates RL, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12\u20138.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"2137_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471\u20136.","journal-title":"J Cardiol"},{"issue":"20","key":"2137_CR31","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","volume":"70","author":"UM Mogensen","year":"2017","unstructured":"Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, et al. type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(20):2490\u2013500.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2137_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Synd. 2020;14(3):181\u20137.","journal-title":"Diabetes Metab Synd"},{"issue":"36","key":"2137_CR33","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, K\u00f8ber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727\u201338.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02137-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T11:03:10Z","timestamp":1708772590000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02137-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2137"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02137-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"12 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}